Facts You Need to Understand Series Stock

By Chris Stiles • Tuesday, September 16 10:07 • Permanent Link

Series logged a -0.2% change during today's morning session, and is now trading at a price of $77.62 per share. The S&P 500 index moved -0.0%. GEHC's trading volume is 276,477 compared to the stock's average volume of 3,784,162.

Series trades -11.79% away from its average analyst target price of $88.0 per share. The 19 analysts following the stock have set target prices ranging from $73.0 to $106.0, and on average have given Series a rating of buy.

If you are considering an investment in GEHC, you'll want to know the following:

Series's current price is 83.1% above its Graham number of $42.39, which implies that at its current valuation it does not offer a margin of safety
Series has moved -10.4% over the last year, and the S&P 500 logged a change of 17.4%
Based on its trailing earnings per share of 4.88, Series has a trailing 12 month Price to Earnings (P/E) ratio of 15.9 while the S&P 500 average is 29.3
GEHC has a forward P/E ratio of 16.6 based on its forward 12 month price to earnings (EPS) of $4.67 per share
Its Price to Book (P/B) ratio is 3.65 compared to its sector average of 3.19
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally.
Based in Chicago, the company has 53,000 full time employees and a market cap of $35.44 Billion. Series currently returns an annual dividend yield of 0.1%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.